CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,079 enrolled
Drug / intervention
Tenofovir disoproxildrug
Likely dose
Tenofovir disoproxil 245 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02129829
NCT02129829N/ACompleted

Prevention of Liver Fibrosis and Cancer in Africa. Observational Study of Screening, Assessment and Treatment for Chronic Hepatitis B Virus Infection

Imperial College London·observational·Posted May 2, 2014·Updated Sep 28, 2020

In Brief

An observational study evaluating Tenofovir disoproxil for Hepatitis B, Chronic and Hepatocellular Carcinoma. Completed, enrolled 1,079 participants across 2 sites in 2 countries.

Detailed Summary

The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA. It aims to evaluate a number of steps required to successfully treat patients with chronic hepatitis B virus infection to prevent cirrhosis and liver cancer. The first step is to determine whether screening for hepatitis B using a point of care test is feasible and effective. The second is to monitor linkage from screening into care. The third is to evaluate cheap non-invasive assessments to determine the need for treatment. The fourth is to determine what proportion of patients meet treatment eligibility criteria. The fifth step is to establish a treatment cohort which can be used to measure adherence to therapy and avoidance of HBV related complications. A parallel untreated cohort will be established to determine whether treatment criteria are relevant in this West African setting by monitoring for complications of HBV infection.

Study Details

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2, 2014
Enrollment StartOct 1, 2011
Primary CompletionJul 31, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 12.2 years ago

Interventions

Tenofovir disoproxildrug

Tenofovir disoproxil 245 mg once daily